Ads
related to: kyprolis- Prescribing Info
See Full Prescribing Info
For ELREXFIO™ (elranatamab)
- Safety Information
Click To See Full Safety Info
For ELREXFIO™ (elranatamab)
- Downloadable Resources
Find Useful HCP Resources
For ELREXFIO™ (elranatamab)
- Support Resources
Access ELREXFIO™ (elranatamab)
Support & PFOT Resources
- Prescribing Info
Search results
Can multiple myeloma be cured? Treatments and outlook
Medical News Today· 4 days agoConsolidation: This is only if a person is to receive a stem cell transplant. Maintenance: This...
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
Zacks via Yahoo Finance· 4 days agoQuarter in Detail Royalty revenues were up 8% year over year to $19.1 million in the first quarter....
Ligand Pharmaceuticals Inc (LGND) Reports Mixed Q1 2024 Results:
Guru Focus· 5 days agoTotal Revenue: Reported at $31.0 million for Q1 2024, exceeding the estimated $27.92 million.Net Income: Surged to $86.1 million from $43.6 million in Q1 2023,
Ligand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
GuruFocus.com via Yahoo Finance· 4 days agoDiscover how Ligand Pharmaceuticals Inc (LGND) kicked off 2024 with strong financial results and strategic expansions, setting a positive tone for the year ahead.
Check Out What Whales Are Doing With AMGN - Amgen (NASDAQ:AMGN)
Benzinga· 6 days agoThe acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras ...
Ligand Pharmaceuticals (NASDAQ:LGND) Posts Earnings Results, Beats Estimates By $3.01 EPS
ETF DAILY NEWS· 4 days agoLigand Pharmaceuticals (NASDAQ:LGND – Get Free Report) released its quarterly earnings results on Tuesday. Ligand Pharmaceuticals had a return on equity of 11.98% and a net margin of 37.80%.
Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Tuesday
ETF DAILY NEWS· 6 days agoLigand Pharmaceuticals (NASDAQ:LGND – Get Free Report) will be announcing its earnings results after the market closes on Tuesday, May 7th. Ligand Pharmaceuticals has set its FY 2024 guidance ...
Amgen (NASDAQ:AMGN) Shares Down 2.7% on Insider Selling
ETF DAILY NEWS· 6 days agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) shares were down 2.7% on Monday after an insider sold shares in the company. The company traded as low as $301.09 and last traded at $302.91. Specifically ...
Ads
related to: kyprolis